Preview Mode Links will not work in preview mode

Keep up to date on mental health news, free CME, and live events. Subscribe to our podcast and join our email list!

Sep 4, 2024

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists.

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objective: After completing this educational activity, you should be better able to:

  • Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings
  • Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence
  • Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed
Joint Accreditation Provider MarkAccreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.

  Estimated Time to Complete: 45 minutes

Released: September 04, 2024*   Expiration: September 03, 2027

*NEI maintains a record of participation for six (6) years.

CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare

Credit Designations: The following are being offered for this activity:

  • Physician: ACCME AMA PRA Category 1 Credits
    • NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
  • Nurse: ANCC contact hours
    • NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour
  • Nurse Practitioner: ACCME AMA PRA Category 1 Credits
    • American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
    • The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics.
  • Pharmacy: ACPE application-based contact hours
    • This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU).
    • The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
  • Physician Associate/Assistant: AAPA Category 1 CME credits
    • AAPA Category 1 CME creditNEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation.
  • Non-Physician Member of the Healthcare Team: Certificate of Participation
    • NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity.
  • Interprofessional Continuing Education: IPCE credit for learning and change
    • Joint Accreditation Provider MarkThis activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted.

Faculty Author / Presenter
Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Malvern, PA

Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences

Faculty Author / Presenter
Charles P. Vega, MD

Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA

Consultant/Advisor: Boehringer Ingelheim, Exact Sciences

The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com.

Support: This activity is supported solely by the provider, NEI.